LENZ Therapeutics (LENZ.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec15

Analysts Maintain 'Buy' Rating on LENZ Therapeutics

20:02

Dec2

LENZ Therapeutics Gets FDA Approval for Presbyopia Treatment Vizz

09:28

Dec1

Lotus Pharmaceutical Submits New Drug VIZZ Application in South Korea

13:30

Nov15

Citigroup Analyst Maintains Buy Rating on LENZ Therapeutics

17:26

Nov5

LENZ Therapeutics released FY2025 9 Months earnings on November 5 During-Market (EST), actual revenue USD 17.5 M, actual EPS USD -1.6521

21:00

LENZ Therapeutics released FY2025 Q3 earnings on November 5 During-Market EST, actual revenue USD 12.5 M (forecast USD 4.643 M), actual EPS USD -0.5851 (forecast USD -0.6666)

21:00

Schedules & Filings

Schedules

Filings

Nov5

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 12.5 M, Net Income -16.7 M, EPS -0.5851

Jul30

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 5 M, Net Income -14.91 M, EPS -0.531

May7

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Net Income -14.62 M, EPS -0.531

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change